• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

西巴尔干国家非传染性疾病的药品供应与处方政策

Medicine Availability and Prescribing Policy for Non-Communicable Diseases in the Western Balkan Countries.

作者信息

Pekez-Pavlisko Tanja, Racic Maja, Kusmuk Srebrenka

机构信息

Family Medicine Clinic "Tanja Pekez-Pavlisko", Kutina, Croatia.

Faculty of Medicine, Department for Primary Health Care and Public Health, University of East Sarajevo, East Sarajevo, Bosnia and Herzegovina.

出版信息

Front Public Health. 2017 Nov 8;5:295. doi: 10.3389/fpubh.2017.00295. eCollection 2017.

DOI:10.3389/fpubh.2017.00295
PMID:29167787
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5682312/
Abstract

BACKGROUND

During the transition processes, the Western Balkan countries were affected by conflicts and transition-related changes. Life expectancy in these countries is lower, while the mortality from non-communicable diseases (NCDs) is higher in comparison with western and northern parts of Europe. The primary aim of this study was to analyze the treatment possibilities for the most common NCDs in the Western Balkan countries. The secondary aim was to understand and compare the policies regarding prescribing-related competencies of family physicians.

METHODS

In June and July 2017, a document analysis was performed of national positive medicines lists, strategic documents, and clinical guidelines for the treatment of the most frequent NCDs; arterial hypertension, diabetes, hyperlipidemia, asthma, and chronic obstructive pulmonary disease (COPD). All text phrases that referred to medicines prescribing were extracted and sorted into following domains: medicine availability, prescribing policy, and medication prescribing-related competencies.

RESULTS

Possibilities for treatment of arterial hypertension, diabetes, hyperlipidemia, asthma, and COPD vary across the Western Balkan countries. This variance is reflected in the number of registered medicines, number of parallels, and number of different combinations, as well as restrictions placed on family physicians in prescribing insulin, inhaled corticosteroids, statins and angiotensin II receptor blockers (ARBs), without consultant's recommendation.

CONCLUSION

Western Balkan countries are capable of providing essential medicines for the treatment of NCDs, with full or partial reimbursement. There are some exceptions, related to statins, newer generation of oral antidiabetic agents and some of the antihypertensive combinations. Prescribing-related competences of family physicians are limited. However, this practice is not compliant to the practices of family medicine, its principles and primary care structures, and may potentially result in increased health-care financial ramifications to both the system and patients due to frequent referrals to the specialists.

摘要

背景

在转型过程中,西巴尔干国家受到冲突和与转型相关的变化影响。这些国家的预期寿命较低,而非传染性疾病(NCDs)的死亡率高于欧洲西部和北部地区。本研究的主要目的是分析西巴尔干国家最常见非传染性疾病的治疗可能性。次要目的是了解和比较关于家庭医生处方相关能力的政策。

方法

2017年6月和7月,对国家积极药品清单、战略文件以及治疗最常见非传染性疾病(动脉高血压、糖尿病、高脂血症、哮喘和慢性阻塞性肺疾病(COPD))的临床指南进行了文献分析。提取所有提及药品处方的文本短语,并分类到以下领域:药品可及性、处方政策和与药物处方相关的能力。

结果

西巴尔干国家在动脉高血压、糖尿病、高脂血症、哮喘和慢性阻塞性肺疾病的治疗可能性方面存在差异。这种差异体现在注册药品数量、仿制药数量、不同组合数量以及在没有顾问建议的情况下对家庭医生开具胰岛素、吸入性糖皮质激素、他汀类药物和血管紧张素II受体阻滞剂(ARBs)的限制上。

结论

西巴尔干国家有能力提供用于治疗非传染性疾病的基本药物,全部或部分予以报销。存在一些例外情况,涉及他汀类药物、新一代口服抗糖尿病药物和一些抗高血压组合。家庭医生的处方相关能力有限。然而,这种做法不符合家庭医学的实践、其原则和初级保健结构,并且由于频繁转诊至专科医生,可能会给系统和患者带来增加的医疗保健财务影响。

相似文献

1
Medicine Availability and Prescribing Policy for Non-Communicable Diseases in the Western Balkan Countries.西巴尔干国家非传染性疾病的药品供应与处方政策
Front Public Health. 2017 Nov 8;5:295. doi: 10.3389/fpubh.2017.00295. eCollection 2017.
2
Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.超越黑木树:影响澳大利亚地区、农村和偏远地区的健康研究问题的快速综述。
Med J Aust. 2020 Dec;213 Suppl 11:S3-S32.e1. doi: 10.5694/mja2.50881.
3
The global impact of non-communicable diseases on households and impoverishment: a systematic review.非传染性疾病对家庭和贫困的全球影响:系统评价。
Eur J Epidemiol. 2015 Mar;30(3):163-88. doi: 10.1007/s10654-014-9983-3. Epub 2014 Dec 21.
4
Factors affecting the uptake of new medicines in secondary care - a literature review.影响二级医疗中新药采用情况的因素——一项文献综述
J Clin Pharm Ther. 2008 Aug;33(4):339-48. doi: 10.1111/j.1365-2710.2008.00925.x.
5
Investing in Public Health Microbiology Laboratories in Western Balkan Countries Enhances Health Security From Communicable Disease Threats in Europe.投资西巴尔干国家的公共卫生微生物实验室可增强欧洲应对传染病威胁的卫生安全。
Front Public Health. 2019 Feb 4;7:8. doi: 10.3389/fpubh.2019.00008. eCollection 2019.
6
National Responses to HIV/AIDS and Non-Communicable Diseases in Developing Countries: Analysis of Strategic Parallels and Differences.发展中国家对艾滋病毒/艾滋病和非传染性疾病的国家应对措施:战略异同分析
J Public Health Res. 2014 Apr 3;3(1):99. doi: 10.4081/jphr.2014.99. eCollection 2014 Mar 26.
7
Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications.多政策提高欧洲已上市药品的处方效率,特别关注需求方措施:发现与未来影响。
Front Pharmacol. 2014 Jun 17;5:106. doi: 10.3389/fphar.2014.00106. eCollection 2014.
8
Availability, prices and affordability of selected antibiotics and medicines against non-communicable diseases in western Cameroon and northeast DR Congo.喀麦隆西部和刚果民主共和国东北部部分抗生素和非传染性疾病药物的可及性、价格和可负担性。
PLoS One. 2020 Jan 7;15(1):e0227515. doi: 10.1371/journal.pone.0227515. eCollection 2020.
9
Baseline assessment of WHO's target for both availability and affordability of essential medicines to treat non-communicable diseases.对世界卫生组织关于治疗非传染性疾病基本药物的可及性和可负担性目标的基线评估。
PLoS One. 2017 Feb 7;12(2):e0171284. doi: 10.1371/journal.pone.0171284. eCollection 2017.
10
The global impact of non-communicable diseases on healthcare spending and national income: a systematic review.非传染性疾病对医疗支出和国民收入的全球影响:系统评价。
Eur J Epidemiol. 2015 Apr;30(4):251-77. doi: 10.1007/s10654-014-9984-2. Epub 2015 Jan 18.

引用本文的文献

1
Serum Biomarkers Associated with Malnutrition and Nutritional Risk in Elderly Primary Care Patients: A Cross-sectional Study from Bosnia and Herzegovina.老年初级保健患者中与营养不良和营养风险相关的血清生物标志物:一项来自波斯尼亚和黑塞哥维那的横断面研究。
Zdr Varst. 2020 Dec 31;60(1):30-37. doi: 10.2478/sjph-2021-0006. eCollection 2020 Dec.
2
Workplace Violence and Sanctioning of Family Medicine Physicians Due to the Rules of Health Insurance Funds in the Western Balkan.西巴尔干地区因健康保险基金规则导致的工作场所暴力及对家庭医学医生的制裁
Mater Sociomed. 2019 Jun;31(2):99-104. doi: 10.5455/msm.2019.31.99-104.
3
An Overview of the Reimbursement Decision-Making Processes in Bulgaria As a Reference Country for the Middle-Income European Countries.

本文引用的文献

1
Associations of fats and carbohydrate intake with cardiovascular disease and mortality in 18 countries from five continents (PURE): a prospective cohort study.五大洲 18 个国家的脂肪和碳水化合物摄入与心血管疾病和死亡率的关系:一项前瞻性队列研究。
Lancet. 2017 Nov 4;390(10107):2050-2062. doi: 10.1016/S0140-6736(17)32252-3. Epub 2017 Aug 29.
2
The 2017 Update to the COPD Foundation COPD Pocket Consultant Guide.慢性阻塞性肺疾病基金会《慢性阻塞性肺疾病袖珍咨询指南》2017年更新版
Chronic Obstr Pulm Dis. 2017 Jul 15;4(3):177-185. doi: 10.15326/jcopdf.4.3.2017.0136.
3
Pharmaceutical expenditure dynamics in the Balkan countries.
保加利亚作为中等收入欧洲国家的参考国的报销决策过程概述
Front Public Health. 2018 Mar 5;6:61. doi: 10.3389/fpubh.2018.00061. eCollection 2018.
巴尔干国家的药品支出动态
J Med Econ. 2017 Oct;20(10):1013-1017. doi: 10.1080/13696998.2017.1333514. Epub 2017 Jun 7.
4
Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015.1990年至2015年全球、区域和国家10种心血管疾病病因负担
J Am Coll Cardiol. 2017 Jul 4;70(1):1-25. doi: 10.1016/j.jacc.2017.04.052. Epub 2017 May 17.
5
Variation in GP decisions on antihypertensive treatment in oldest-old and frail individuals across 29 countries.29个国家中最年长和体弱个体的全科医生关于抗高血压治疗决策的差异。
BMC Geriatr. 2017 Apr 20;17(1):93. doi: 10.1186/s12877-017-0486-4.
6
Critical Appraisal of Reimbursement List in Bosnia and Herzegovina.波斯尼亚和黑塞哥维那报销清单的批判性评估。
Front Pharmacol. 2017 Mar 17;8:129. doi: 10.3389/fphar.2017.00129. eCollection 2017.
7
Within the triangle of healthcare legacies: comparing the performance of South-Eastern European health systems.在医疗保健遗产三角区内:比较东南欧卫生系统的绩效。
J Med Econ. 2017 May;20(5):483-492. doi: 10.1080/13696998.2016.1277228. Epub 2017 Jan 17.
8
Pharmaceutical Expenditure and Burden of Non-communicable Diseases in Serbia.塞尔维亚的药品支出与非传染性疾病负担
Front Pharmacol. 2016 Oct 13;7:373. doi: 10.3389/fphar.2016.00373. eCollection 2016.
9
Quality of care for patients with diabetes mellitus type 2 in 'model practices' in Slovenia - first results.斯洛文尼亚“示范诊所”中2型糖尿病患者的护理质量——初步结果
Zdr Varst. 2016 May 10;55(3):179-184. doi: 10.1515/sjph-2016-0023. eCollection 2016 Sep 1.
10
UTILISATION ANALYSIS OF ANTIHYPERTENSIVE DRUGS IN BOSNIA AND HERZEGOVINA FOR THE TIME-PERIOD 2013-2015.2013 - 2015年期间波斯尼亚和黑塞哥维那抗高血压药物的使用情况分析
Mater Sociomed. 2016 Apr;28(2):116-20. doi: 10.5455/msm.2016.28.116-120. Epub 2016 Mar 25.